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Summary
Background: The breast and ovarian cancer suppressor
BRCA1 is essential for cellular responses to DNA damage
[1]. It heterodimerizes with BARD1 to acquire an E3 ubiquitin
(Ub) ligase activity that is often compromised by cancer-asso-
ciated mutations [2]. Neither the significance of this activity to
damage responses, nor a relevant in vivo substrate, is clear.
Results: We have separated DNA-damage responses re-
quiring the BRCA1 E3 ligase from those independent of it,
using a gene-targeted point mutation in vertebrate DT40 cells
that abrogates BRCA1’s catalytic activity without perturbing
BARD1 binding. We show that BRCA1 ubiquitylates claspin,
an essential coactivator of the CHK1 checkpoint kinase, after
topoisomerase inhibition, but not DNA crosslinking by mito-
mycin C. BRCA1 E3 inactivation decreases chromatin-bound
claspin levels and impairs homology-directed DNA repair by
interrupting signal transduction from the damage-activated
ATR kinase to its effector, CHK1.
Conclusions: Our findings identify claspin as an in vivo
substrate for the BRCA1 E3 ligase and suggest that its modifi-
cation selectively triggers CHK1 activation for the homology-
directed repair of a subset of genotoxic lesions. This mecha-
nism unexpectedly defines an essential but selective function
for BRCA1 E3 ligase activity in cellular responses to DNA
damage.
Introduction
There is abundant evidence that the breast and ovarian tumor
suppressor, BRCA1, has essential functions in diverse cellular
processes implicated in the DNA damage response [1]. How
BRCA1 mediates these functions remains unclear. Much
attention has focused on the E3 ubiquitin ligase activity
acquired when BRCA1 heterodimerizes through its amino-
terminal RING domain with an evolutionarily conserved RING
partner, BARD1 [3]. Deleterious missense mutations affecting*Correspondence: arv22@cam.ac.ukthe BRCA1 RING domain can be found in familial breast
cancers that do not vitiate BARD1 binding but can neverthe-
less abolish E3 ligase activity [2, 4], suggestive of its functional
importance. However, a BRCA1 point mutation abolishing E3
activity does not impair ionizing radiation sensitivity or the
repair of endonuclease-induced DNA breaks by homologous
recombination [5]. Furthermore, mice harboring the mutation
do not develop breast cancers [6]. On the other hand, inactiva-
tion of BRCA1 E3 ligase activity can derepress heterochro-
matic satellite DNA transcription, an event that has been linked
to abnormalities in DNA repair andmitosis [7]. Thus, if and how
BRCA1’s E3 ligase activity is necessary for the cellular
response to DNA damage remains uncertain.
BRCA1 has been implicated in several processes essential
for the cellular response to DNA lesions repaired by homolo-
gous recombination [1]. One key step involves activation of
the checkpoint kinase CHK1, an essential component of the
damage response machinery in vertebrates. Phosphorylation
of CHK1 occurs on chromatin. The phosphorylated CHK1 is
released from chromatin and the dissociation is required for
checkpoint activation [8]. BRCA1 has been implicated in
CHK1 activation via ATR and claspin. ATR-phosphorylated
claspin forms a trimolecular complex containing BRCA1 and
CHK1 [9]. Complex formation is essential for CHK1 phosphor-
ylation and activation [9]; in turn, activated CHK1 mediates
checkpoint enforcement as well as DNA repair by homologous
recombination [10, 11], through modulation of the interaction
between BRCA2 and the recombinase RAD51 [12, 13].
However, the mechanism through which BRCA1 controls the
claspin-CHK1 axis, and in particular, whether its E3 ligase
activity is required, is not known.
Here, we have used ‘‘hit-and-run’’ gene targeting to create
a DT40 cell line carrying a single mutation in BRCA1, replacing
Val26 in the RING domain with Ala (V26A). The V26A mutation
abrogates E3 ligase activity without affecting the interaction
between BRCA1 and BARD1. Unexpectedly, E3 inactivation
reveals a mechanism distinguishing DNA damage responses
that requireBRCA1’s catalytic activity, from those independent
of it. Whereas the BRCA1 E3 ligase is essential for chromatin
associationofclaspinandCHK1activationwhena topoisomer-
ase poison, camptothecin (CPT), blocks DNA replication, it is
dispensable for these events after replication blockage by
a DNA crosslinker, mitomycin C (MMC). In turn, downstream
responses regulatedbyCHK1, includingRAD51 foci formation,
sister chromatid exchange, and cellular sensitivity, are selec-
tively impaired after exposure to CPT, but not MMC. Thus,
ourworksuggests that theBRCA1E3 ligaseselectively triggers
claspin-CHK1 activation, providing the first example of an E3-
dependent mechanism underlying an essential function for
BRCA1 in the cellular response to DNA damage.
Results and Discussion
BRCA1 has been implicated in the cellular response to
DNA double-strand breaks leading to their resolution by
homology-directed repair (HDR) [1]. We used avian DT40 cells,
a well-established model widely used to study the role of
BRCA1 in this response [14–16], to determine the functional
Figure 1. The V26A Point Mutation Defines a
Subset of Genotoxic Responses Requiring
BRCA1 E3 Ligase Activity
(A and B) Cell viability, as determined by the Cell-
Titer Blue colorimetric assay, is expressed as a
percentage of the untreated control sample for
both cell lines. The percentage of viable cells is
plotted for each of the indicated doses of mito-
mycin C (MMC) (A) and camptothecin (CPT) (B).
Error bars (some too small to be visible) show
the SD from the mean of four independent wells
from three independent experiments.
(C) Representative micrographs of WT or V26A
DT40 cells, undamaged (top row) or treated for
6 hr with the indicated drugs (rows 2–4) and
stained with anti-RAD51 (grayscale). DNA stain-
ing was with DAPI (blue).
(D) Histogram showing the percentage of cells
with >5 RAD51 foci. RAD51 foci were counted in
WT and V26A cells (n = 100) before and after
exposure to the indicated drugs (MMC: 150 nM
for 8 hr, CPT: 100 nM for 8 hr). Error bars show
the SD from the mean of three independent
experiments.
(E and F) Histograms showing the frequency
distribution for spontaneous, MMC (150 nM for
8 hr) or CPT (100 nM for 8 hr)-induced sister chro-
matid exchanges (SCE’s) in WT (E) or V26A DT40
cells (F). Spontaneous SCE formation is intact,
but only MMC (gray color bars) induces SCEs
in V26A mutant cells. See also Figure S1 and
Table S1.
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homologs, Ile26 in the RING domain is implicated in binding to
E2 ubiquitin conjugating enzymes [2]. Its substitution by Ala
abolishes BRCA1’s E3 ligase activity without affecting hetero-
dimerization to BARD1 [2]. Val26 in the avian RING domain
conservatively replaces Ile26 in its mammalian counterparts,
reflecting their strong evolutionary conservation (see Fig-
ure S1A available online). We cloned the RING domains of
avian BRCA1 and BARD1 from a DT40 complementary DNA
(cDNA) library and introduced the Val26Ala (V26A) point muta-
tion by site-directed mutagenesis. When cotransfected into
293T cells with the avian BARD1 RING domain, the V26A
mutant form of the GgBRCA1 RING domain still binds to the
BARD1 RING domain (Figure S1B) but fails to catalyze the
transfer of ubiquitin in vitro (Figure S1C). Thus, replacement
of Val26 with Ala in avian BRCA1 abolishes the E3 ligase
activity of the RING domain but not its interaction with
BARD1. This confirms that avian Val26 is functionally cognate
with Ile26 in mammalian BRCA1.
Figure S1D shows the gene-targeting strategy used to
create a DT40 cell line carrying a Val26-Ala substitution in theendogenous BRCA1 gene. The targeting
vector carries a blasticidin or neomycin
resistance cassette flanked by loxP sites
for the CRE recombinase, enabling recy-
cling of the resistance marker by CRE
transfection between sequential rounds
of targeted integration. Homozygous
Val26-Ala replacement was confirmed
by amplification of the targeted BRCA1
genomic locus using the indicated
primers (Figure S1D), by a diagnostic
restriction digest with BsrDI (Figure S1E)and by nucleotide sequencing (data not shown). Western blot-
ting of extracts from BRCA1 wild-type (WT) or BRCA1V26A/V26A
(V26A) cells confirmed that theWTandmutant BRCA1proteins
were expressed at similar levels (Figures S1F and S1G). Thus,
in accord with previous reports [14, 15], BRCA1 E3 ligase is
dispensable for the viability and growth of DT40 cells.
BRCA1 has been implicated in the cellular response to
agents that inflict DNA lesions repaired by HDR. These include
the topoisomerase I poison, camptothecin (CPT), which trig-
gers DNA breakage at replication forks [17], or the DNA cross-
linking agent, mitomycin C (MMC), which creates intrastrand
lesions aswell as interstrand crosslinks that prevent themove-
ment of replication forks [18]. We exposedWT or V26A cells to
increasing doses of CPT or MMC for 40 hr before measuring
cell viability (Figures 1A and 1B). V26A cells exhibit enhanced
sensitivity to CPT, but not MMC. This raises the unexpected
possibility that BRCA1 E3 ligase activity is selectively required
for certain cellular responses leading to the repair of certain
types of DNA lesions by HDR, but not others.
Two key cellular events report on the integrity of HDR in
DT40 cells. First, inactivating mutations in known HDR
Figure 2. BRCA1 Ubiquitylates Claspin In Vitro
and In Vivo in Cells Exposed to CPT but Not MMC
(A) 293T cells were transfected with constructs
encoding FLAG-claspin, a myc-tagged BRCA1
fragment spanning residues 1–772 (myc-BRCA1
1–772 WT or I26A mutant), BARD1, or HA-ubiqui-
tin as indicated. Cell lysates were prepared 24 hr
afterward, immunoprecipitated with anti-FLAG
antibody, and blotted with anti-HA and anti-
FLAG antibodies, as indicated. The HA-tagged,
ubiquitylated form of FLAG-claspin is present
only when both myc-BRCA1 WT 1–772 and
BARD1 are coexpressed. Whole-cell lysates
were immunoblotted with anti-FLAG to show
the expression level of FLAG-claspin and with
anti-a-tubulin as a loading control.
(B) In vitro ubiquitin ligation assay was performed
with a GST-FLAG tagged claspin fragment span-
ning residues 1–331 (GST-FLAG claspin 1–331),
E1, UbcH5c, ubiquitin, and BRCA1/BARD1
RING heterodimeric complex as indicated, in
the presence of ATP. Reaction products were im-
munoblotted with anti-GST antibody.
(C) WT or V26A DT40 cells were treated with CPT
(100 nM) for 3 hr or MMC (150 nM) for 6 hr. Cell
lysates were immunoprecipitated with FK2 (anti-conjugated ubiquitin antibody) and western blotted with anti-Ggclaspin. ‘‘C’’ and ‘‘M’’ indicate treatment
with CPT and MMC respectively. Ubiquitin-conjugated claspin was detected only in CPT-treated WT cells (top panel). Blotting with anti-b-actin serves as
a loading control. See also Figure S2.
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1661proteins, including BRCA1 deletions [14], suppress the accu-
mulation of the recombination enzyme RAD51 in nuclear foci
at sites of DNA repair. Second, such mutations also inhibit
the spontaneous or genotoxin-induced exchange of genetic
material between sister chromatids (sister chromatid ex-
change, SCE), a direct measure of HDR [19]. Consistent with
their enhanced sensitivity to CPT, V26A cells exhibit a diminu-
tion in their ability to form RAD51 foci in response to these
agents, when compared toWT cells (Figures 1C and 1D). Inter-
estingly, such a defect is not apparent when these cell lines are
exposed to MMC, consistent with their lack of sensitivity to
this genotoxin. Similarly, the V26A mutation in BRCA1 also
suppresses SCE formation induced by CPT, but not MMC
(Figures 1E and 1F; Table S1) even though spontaneous SCE
formation in V26A cells is slightly greater than in WT controls.
Because SCE formation is a direct measure of crossover
events mediated by HDR [19], our findings indicate that
BRCA1 E3 activity is dispensable for the execution of DNA
repair by this pathway in response to spontaneously arising,
or MMC-induced, DNA damage. Instead, they reveal a more
selective requirement for BRCA1’s catalytic activity in the
repair of CPT-induced lesions by HDR.
To identify substrates for BRCA1 E3 ligase relevant to this
dichotomous role, we examined claspin, a critical coactivator
of the damage-activated checkpoint kinase CHK1 necessary
for HDR [9, 20]. BRCA1 forms a trimolecular complex with
CHK1 and claspin through its direct binding to claspin,
although how it promotes their activation remains unknown
[9]. We therefore tested whether claspin itself might be an
unrecognized target for modification by the E3 ligase activity
of BRCA1. A myc-tagged fragment spanning residues 1 to
772 of BRCA1, which forms an active E3 ligase enzyme when
cotransfected with BARD1 [3], can conjugate hemagglutinin
(HA)-tagged ubiquitin (Ub) to FLAG-claspin (Figure 2A). This
activity is abrogated by omission of either BARD1 or BRCA1,
or expression of the BRCA1 I26Amutant, confirming that clas-
pin modification requires the heterodimeric E3 enzyme. To
identify the regions of claspin that can undergo modification,we first tested four fragments each of about 350 amino acids
dividing claspin at well-established domain boundaries [21].
The N-terminal fragment spanning residues 1–331 was highly
ubiquitylated compared to other fragments (data not shown).
The copurified recombinant BRCA1/BARD1 heterodimeric
complex is able to ubiquitylate this N-terminal claspin frag-
ment in an in vitro Ub ligation assay (Figure 2B), indicating
that it is a candidate substrate for the BRCA1 E3 ligase.
Many candidate substrates for the BRCA1 E3 ligase have
been identified in vitro, but none has so far been confirmed
in cellular studies [22]. We therefore asked whether claspin
ubiquitylation could be detected in cells and whether this
modification reflected the dichotomous requirement we have
identified for BRCA1 E3 ligase activity in the response to
CPT but not MMC. We exposed WT or V26A cells to these
agents before cell lysates were immunoprecipitated with an
antibody to conjugated ubiquitin (FK2), followed by western
blotting with an anti-Ggclaspin antibody. Strikingly, the Ub
conjugation of endogenous claspin was induced in response
to CPT (but not MMC) in WT (but not V26A) cells (Figure 2C).
One predominant Ub-conjugated claspin species is observed,
consistent with our overexpression experiments in 293T, in
which FLAG-claspin was modified with HA-ubiquitin (Fig-
ure 2A). These observations suggest that the BRCA1 E3 ligase
does indeed selectively ubiquitylate claspin in cells exposed to
CPT but not MMC, and provide a first example of in vivo
substrate ubiquitylation by this enzyme during a biological
process.
We identified the sites of BRCA1/BARD1-mediated ubiquitin
conjugation in the N-terminal claspin fragment spanning resi-
dues 1–331 by mass spectrometry (Figures 3A and 3B; Table
S2). Analysis of tryptic digests of this claspin fragment after
in vitro ubiquitylation by BRCA1/BARD1 revealed four poten-
tial conjugation sites (Table S2). Covalent linkage of a di-Gly
motif introduced by substrate ubiquitylation at Lys60 and
Lys96 was unambiguously identified in two independent frag-
ment-ion spectra each, whereas Lys89 and Lys105 were iden-
tified in only one spectrum each (Figures 3A and 3B).
Figure 3. BRCA1-Mediated Claspin Ubiquitylation Targets N-Terminal Lys Residues
(A andB) The fragment ion spectra show the claspin tryptic peptides K*VLQDSDSETEDTNASPEK (A) and TTYDSAEEENKENLYAGK*NTK (B) and confirm the
presence of a double glycine (GG) modification at Lys-60 as well as at Lys-96, assigning unambiguously the site of ubiquitylation (indicated by an asterisk
modification).
(C)Multispecies protein sequence alignment of amino-terminal claspin residues 41–101. * indicates that the residues are identical. ‘‘:’’ indicates that residues
have conserved substitutions. Lysine residues highlighted in bold were mutated to arginine.
(D) 293T cells were transfected with FLAG-claspin (WT or the NT-KR mutant), HA-ubiquitin, myc-BRCA1 1–772 (WT or I26A mutant), and BARD1 as indi-
cated. Cell lysates were subjected to sequential immunoprecipitation and western blotting with anti-FLAG and anti-HA antibodies respectively. Five percent
of the input per immunoprecipitation was blotted with the indicated antibodies. Ubiquitylation of the NT-KR claspin mutant is reduced compared toWT. See
also Figure S3 and Table S2.
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claspin across multiple species that also have a known
BRCA1 ortholog demonstrated that Lys60 was found in
a region of high sequence conservation that also contained
additional conserved basic residues. In contrast, the sequence
surrounding Lys96 is less well conserved (Figure 3C). Taken
collectively, these findings suggest that Lys60 represents an
evolutionarily conserved modification site on claspin, and
that the protein may also be modified by Ub conjugation at
additional Lys residues in its N-terminal region.
In fact, three conserved lysines (Lys54, Lys55, and Lys57)
occur in the six residues N-terminal to Lys60. Because site-
specific ubiquitylation becomes promiscuous if the preferred
Lys target is absent but a neighboring alternative acceptorlysine is present [23], we created a mutant form of claspin
(NT-KR) in which all four Lys residues at positions 54, 55, 57,
and 60 were changed to Arg. WT or NT-KR mutant forms of
claspin were cotransfected into 293T cells with BRCA1/
BARD1 in the presence of HA-ubiquitin. Ub conjugation to
WT claspin was evident when BRCA1/BARD1 were coex-
pressed, and decreased by expression of the BRCA1 I26A
mutant (Figure 3D). Moreover, the NT-KR claspin mutant
shows reduced modification compared to the WT form.
Together, these data suggest that BRCA1/BARD1 conjugates
Ub to Lys60 and adjacent residues in the N-terminus of
claspin.
Because CHK1 is phosphorylated on chromatin when form-
ing a complex with BRCA1 and claspin, we tested whether
Figure 4. BRCA1 E3 Inactivation Decreases
Chromatin-Bound Claspin and Suppresses
CHK1 Activation Specifically in Response to
CPT but Not MMC
(A) 293T cells were transfected with constructs
encoding either WT or NT-KR mutant forms of
claspin. Thirty-six hours after transfection, cells
were fractionated into cytoplasmic and nuclear
soluble (S1 + S3) or chromatin-bound (P3) frac-
tions, and immunoblotted with the indicated
antibodies. SCC1 and MEK2 serve as controls
for loading and the effectiveness of fractionation.
‘‘C’’ and ‘‘M’’ indicate treatment with CPT and
MMC, respectively. Untreated cells were
included as controls. Claspin NT-KR levels in
the chromatin-bound fraction are diminished in
response to CPT, but not MMC.
(B) WT and V26A DT40 cells were incubated with
CPT (100 nM) for 1 hr or MMC (150 nM) for 6 hr.
Lysates were fractionated into cytoplasmic and
nuclear soluble (S1 + S3) or chromatin-bound
(P3) fractions and immunoblotted with the indi-
cated antibodies. SCC1 and MEK2 serve as
controls for loading and the effectiveness of frac-
tionation. ‘‘C’’ and ‘‘M’’ indicate treatment with
CPT and MMC, respectively. Untreated cells
were included as controls. Claspin levels in the
chromatin-bound fraction of V26A cells are
diminished in response to CPT, but not MMC.
(C) WT and V26A DT40 cells were treated with
CPT (100 nM) for 1 hr or MMC (150 nM) for 6 hr.
Whole-cell extracts were immunoblotted with
the indicated antibodies. Untreated cells are
included as controls. ‘‘C’’ and ‘‘M’’ indicate treat-
ment with CPT and MMC, respectively. Ser345
phosphorylation of CHK1 is impaired in V26A
cells only in response to CPT.
(D) We propose that genotoxic lesions generated
by CPT (upper panel, left) require BRCA1/BARD1
E3 ligase activity, which ubiquitylates claspin to
promote CHK1 phosphorylation (pCHK1, center)
and homology-directed repair. Lesions such as
those generated by MMC bypass this pathway
(upperpanel, right),separatingBRCA1E3-indepen-
dent from -dependent DNA damage responses.
TheE3ligase-inactiveBRCA1V26Amutant is there-
fore defective for the response to CPT, but not
MMC (lower panel). See also Figure S4.
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To do this, we compared the levels of WT or NT-KR mutant
claspin in the soluble (S1+S3) or chromatin-bound (P3) frac-
tions of nuclear extracts prepared from 293T cells exposed
to these agents (Figure 4A). WT claspin is detected in both
the soluble and chromatin-bound protein fractions of nuclear
extracts. In contrast, NT-KRmutant claspin does not accumu-
late in the chromatin-bound protein fraction in cells exposed to
CPT. Indeed, a similar difference is observed when the levels
of claspin were measured in WT or V26A cells treated with
CPT or MMC (Figure 4B). Claspin levels in the soluble fraction
are similar in both cell types, before (2) and after exposure to
CPT or MMC, with a slight reduction in V26A cells exposed to
CPT (compare lanes 2 and 3 with 5 and 6 in row 1). In the chro-
matin-bound fraction, claspin expression in untreated V26A
cells, or even in V26A cells exposed to MMC, is similar to the
levels found in WT cells. Remarkably, however, in the chro-
matin-bound protein fraction prepared from V26A cells
exposed to CPT, claspin is specifically diminished in compar-
ison toWTcontrols (compare lanes 2, 5, in row 4). Interestingly,the diminution in chromatin-bound claspin after CPT exposure
is not accompanied by a reduction in its retention time
measured by fluorescence recovery after photobleaching
(FRAP, Figures S2A–S2C). Instead, we observe a reduction in
the half-life of NT-KRmutant claspin relative to theWT (Figures
S2D and S2E). Together, these results suggest that ubiquityla-
tion of claspin by BRCA1/BARD1 is required for its accumula-
tion in the chromatin-bound protein fraction in response to
CPT and may exert this effect via the control of protein
stability.
We therefore analyzed the effect on DNA-damage signaling
of decreased chromatin-bound claspin levels in V26A cells
exposed toCPT.We first investigated the steps leading to acti-
vation of the ataxia and Rad3-like (ATR) kinase, because clas-
pin is known to coactivate CHK1 in an ATR-dependent manner
[9, 20]. We find that the phosphorylation of MCM2 at Ser108,
a known target for ATR phosphorylation after DNA damage
[24], is induced above predamage levels after the exposure
of WT cells to CPT or MMC (Figure 4C, lanes 2 and 3). MCM2
S108 phosphorylation was elevated even in undamaged
Current Biology Vol 22 No 18
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exposure. This may reflect that endogenously arising DNA
lesions in dividing V26A cells (marked by the increased basal
level of SCE formation (Table S1; Figure 1F) constitutively
elevate the resting level of ATR-dependent checkpoint activa-
tion. Nevertheless, these findings suggest that BRCA1 E3
inactivation does not prevent ATR-activated phosphorylation
of MCM2 per se.
In contrast, the phosphorylation of CHK1, an evolutionarily
conserved and essential component of the machinery for
checkpoint enforcement and DNA repair by HDR [10, 13], is
selectively compromised after CPT exposure by the V26A
mutation in BRCA1. ATR phosphorylates CHK1 on residues
Ser317 and Ser345 [10, 25]. These modifications accompany
and are essential for CHK1 activation mediated by ATR [10,
25] and are therefore used as surrogate markers for this event
[25]. Although MMC triggers CHK1 modification on Ser345
in V26A as well as WT cells (Figure 4C, lanes 3 and 6), phos-
phorylation of this Ser residue is selectively impaired in V26A
cells after exposure to CPT (compare lanes 2 and 5). Thus
collectively, our observations indicate that inactivation of
the E3 ligase activity of BRCA1 causes a specific failure in
signal transmission from ATR to CHK1 in response to CPT,
but not MMC.
CHK1 activation triggered by DNA damage occurs on chro-
matin [8]. Claspin forms a trimolecular complex with BRCA1
and CHK1 that is essential for CHK1 activation [9], and its turn-
over is reported to regulate CHK1 activation during recovery
from damage-induced G2 arrest [26, 27]. In this light, our find-
ings suggest amechanism (Figure 4D) wherein ubiquitin conju-
gation to claspin by the BRCA1 E3 ligase promotes efficient
CHK1 activation by maintaining chromatin-bound claspin
levels after replication blockage triggered by CPT but not
MMC. In turn, activated CHK1 mediates checkpoint enforce-
ment [10] aswell as DNA repair by homologous recombination,
throughmodulation of the interaction between BRCA2 and the
recombinase, RAD51 [12, 13]. Thus, our results suggest a novel
role for claspin ubiquitylation by BRCA1 E3 ligase activity in
selectively promoting thehomology-directed repair of a subset
of genotoxic lesions.
Why the claspin-CHK1 axis should require BRCA1 E3 ligase
activity in response to CPT but not MMC is presently unclear.
CPT traps a reversible, cleavable DNA structure by inhibiting
the religation step during topoisomerase I-catalyzed reactions
[28]; the reversible complex is then converted into irreversible
strand breaks upon encounter with the machinery for DNA
replication. MMC triggers intrastrand lesions as well as DNA
crosslinks, which blockDNA replication forks; strandbreakage
accompanies their repair [18]. Thus, both genotoxins induce
lesions that block DNA replication and whose repair by homol-
ogous recombination involves strand-break intermediates.
However, there is insufficient knowledge to speculate what
may distinguish these lesions or repair intermediates structur-
ally to explain the differential requirement for BRCA1 activity in
their resolution. Intriguingly, we find that V26Amutant cells are
selectively more sensitive than their WT counterparts to the
effect of several drugs that inhibit topoisomerase I (CPT,
SN38) as well as topoisomerase II (doxorubicin, etoposide),
but not to MMC (Figures S3A–S3E). Moreover, V26A mutant
cells fail to activate CHK1 Ser345 phosphorylation in response
to topoisomerase inhibitors at doses that suffice to evoke this
response in WT cells (Figure S3F), further supporting the
notion that BRCA1 E3 ligase activity is required for CHK1
activation in response to a subset of genotoxic lesions.Our demonstration that BRCA1 E3 ligase activity is required
for the response to some, but not all, genotoxic lesions
provides new functional insight apposite to recent work con-
cerning BRCA1’s biological role. Recent reports suggest that
themurine BRCA1 point mutation I26A, functionally analogous
to the avian V26A mutation used here, neither affects ionizing
radiation sensitivity, nor the repair of endonuclease-induced
DNA breaks by homologous recombination [5]. Furthermore,
mice harboring this mutation do not develop breast cancers
[6]. However, a different BRCA1 point mutation that abolishes
both E3 ligase activity and BARD1 binding potentiates cellular
sensitivity to poly-ADP ribose polymerase (PARP) inhibition
and cisplatin, and mice carrying this mutation do develop
breast cancer [29]. Notably, at least some of the BRCA1
missense mutations found in familial breast cancer patients
abolish E3 ligase activity without impairing BARD1 binding
[4], like the V26A mutation used in our work, but in contrast
to the murine I26A mutation. Moreover, we find that overex-
pression of the NT-KR mutant of claspin in human cells
depleted of the endogenousWT protein by RNAi has amodest
effect on CPT sensitivity but does not affect sensitivity toMMC
(Figures S4A–S4C), consistent with the results reported here.
Thus, in light of the possible differences between model
systems and species, further exploration of the selective
requirement for BRCA1 E3 activity in the response to certain
forms of DNA damage that we have identified in this work
seems warranted.
Our observations, if confirmed in human cancer cells, could
have potential implications for the treatment of BRCA1-defi-
cient familial cancers in which mutations selectively impair
E3 ligase activity without creating a nullizygous phenotype
[4]. Our findings suggest that there may be benefit in such
a setting from treatment with CPT but not MMC. We speculate
that this may also apply to some of the w10% of sporadic
cancers belonging to the basal-like group, which exhibit
certain phenotypic characteristics suggestive of impaired
but not absent BRCA1 deficiency [30, 31]. These hypotheses
warrant further investigation.
Experimental Procedures
Cell Culture
293T cells were cultured in Dulbecco’s modified Eagle medium supple-
mented with 10% fetal bovine serum and 1% antibiotic-antimycotic agent
at 37C. DT40 cells were maintained in RPMI-1640 medium (GIBCO-BRL)
supplemented with 1025 M b-mercaptoethanol, 10% fetal calf serum
(FCS), 1% antibiotic-antimycotic agent, and 5% chicken serum (GIBCO-
BRL) at 39C.
Plasmids
cDNA of GgBRCA1 (1–222) and GgBARD1 (1–159) were amplified by
PCR from a cDNA pool generated with SuperScript III First-Strand
Synthesis System (Invitrogen) with Pfx DNA polymerase (Invitrogen)
and subcloned into p3X-FLAG-CMV or pcDNA3-myc vectors. For the
purification of GgBRCA1 (1–300), cDNA was amplified by PCR as above
and subcloned into pGEX-4T3 vector in frame with FLAG amino-terminal
tag. For cDNA of GgBRCA1 V26A, both 1–222 and 1–300, were obtained
from the cDNA pool derived from V26A cells with same method outlined
above. Myc-tagged HsBRCA1(1–772), HsBARD1, His-tagged HsBARD1,
and HA-tagged-HsUbiquitin were described previously [32]. cDNA of
Hsclaspin was purchased from Geneservice and PCR was performed
to ligate into p3XFLAG-CMV or pcDNA3.1-Hygro (in frame with NH2-
terminal EGFP tag) vectors. The missense mutant of claspin (NT-KR)
was generated by site-directed mutagenesis. Truncation mutant of
claspin (1–331) was generated by introducing an in-frame NotI or BamHI
site and a stop codon in the appropriate position by site-directed muta-
genesis followed by digestion with either NotI or BamHI to remove the
fragment.
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The sequences of the oligonucleotide primers used here are in Supple-
mental Experimental Procedures. The homologous sequences of avian
BRCA1 used for targeting were isolated by PCR from DT40 genomic DNA
using primers LA F1, LA R1 for left homology arm and RA F1, RA R1 for right
homology arm and cloned into a targeting vector bearing either a neomycin
or blasticidin resistant cassette. The V26A mutation and BsrDI diagnostic
(silent mutation) restriction site were generated by site-directed mutagen-
esis using the Quickchange Site-Directed Mutagenesis Kit (Stratagene).
Heterozygous cells were subjected to a second round of targeting and
homozygous mutant cells were screened by PCR using primer DV26A and
LAR1 (Figure 2A) followed by digestion with BsrDI.
Antibodies
The rabbit polyclonal anti-GgBRCA1 antibodies were raised against the
recombinantly expressed N-terminal 300 amino acids of avian BRCA1
protein. Anti-Ggclaspin antibody was generously provided by Dr. David
Gillespie (Beatson Institute for Cancer Research, Glasgow). Other anti-
bodies used in this study were as follows: anti-FLAG (M2) and anti-b-actin
(AC-15) antibodies (Sigma); anti-Myc (9E10), anti-ATR (N-19), and anti-
CHK1 (G-4) antibodies (Santa Cruz Biotechnology); anti-phospho-ATM
(S1981) and anti-phospho-CHK1 (S345) (Cell Signaling Technology);
anti-RAD51 (Ab-1) (Calbiochem); and anti-HA (12CA5) (Roche). All western
blotting or immunofluorescence reagents were used at the dilutions recom-
mended by the manufacturers.
Drug Sensitivity Assay
Cells were plated into 96-well plates at a density of 8,000 cells per well.
Different doses of mitomycin C (Sigma) and camptothecin (Sigma) were
added, and the plates were incubated at 39C for 40 hr. Cell Titer-Blue
reagents (Promega) were added to each well of the 96-well plate according
to the manufacturer’s guidelines. The plates were incubated at 37C for
approximately 1–2 hr in a humidified 5% CO2 atmosphere. The intensity of
Titer-Blue signal, and thus a fraction of viable cells per well was determined
using the Fusion Plate Reader (Perkin Elmer/Packard) at A590 nm. Each
experiment was done in quadruplicate.
Western Blots and Immunoprecipitation
293T cells were transfected by a standard calcium chloride method. Thirty-
six hr after transfection, cells were lysedwith 0.5%NP-40 lysis buffer (50mM
Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM DTT, 1 mM
Na3VO4, complete protease inhibitor cocktail [Roche], and 1 mM PMSF).
To detect ubiquitylation in vivo, we lysed cells with 1% SDS lysis buffer
(1% SDS, 0.5 mM EDTA, 1 mM DTT and 50 mM Tris HCl pH 7.5) at 100C
for 10 min. After collecting supernatant, the lysate was diluted 10 times in
NP40 lysis buffer for immunoprecipitation. Immunoprecipitates were
washed extensively in NP-40 lysis buffer and resolved by SDS-PAGE. For
fractionation, cells were lysed with buffer A (10 mM HEPES pH 7.9, 10 mM
KCl, 1.5 mM MgCl2, 0.034 M sucrose, 10% glycerol, 1 mM DTT, 100 mM
PMSF, complete protease inhibitor cocktail [Roche], 5 mM Na3VO4,
10mMNaF, 1 mMOkadaic acid) with 0.1%Triton X-100 for 5min on ice. Cells
were centrifuged at 1300 3 g for 4 min and supernatant collected (S1). S1
was further clarified by high speed centrifugation. The nuclei (P1) were
washed in buffer A, then lysed by buffer B (3 mM EDTA, 0.2 mM EGTA,
1 mM DTT, PMSF, complete protease inhibitor cocktail [Roche], 5 mM
Na3VO4, 10mMNaF, 1 mMOkadaic acid) for 1 min on ice. Nuclei were centri-
fuged at 1,7003 g for 4min. Soluble nuclear fraction (S3) was collected. The
insoluble chromatin pellet was then resuspended in buffer A with 1 mM
CaCl2 and 0.2 U micrococcal nuclease, incubated at 37
C for 10 min. Chro-
matin fraction (P3) was collected by high speed centrifugation.
Immunofluorescence Microscopy
To detect RAD51 foci, we spun cells onto glass slides by using a cytocentri-
fuge (Shandon). After drying for 5 min, cells were fixed with 4% paraformal-
dehyde for 10min at room temperature. Sampleswere solubilizedwith 0.2%
Triton X-100 for 5 min and blocked with 3% BSA in 1xPBS, 0.1% Tween-20,
0.1%Triton X-100 (PBST) for 15 min. Cells were then probed with a rabbit
polyclonal anti-RAD51 antibody diluted 1:1,000 for 30 min.
Sister Chromatid Exchange Assay
The sister chromatid exchange assay was performed as described previ-
ously [33]. Briefly, cells were cultured for two cell cycles in the presence
of 10 mM bromodeoxyuridine and with or without 10 nM camptothecin
(CPT) and 150 nM mitomycin C (MMC) for the second cell cycle. Cellswere pulsed with 100 ng/ml colcemid for 3 hr before harvest. Cells were
hypotonically swollen in 75 mM KCl for 20 min at room temperature before
fixation in freshly prepared Carnoy’s solution (methanol: acetic acid, 3:1) for
30 min at room temperature. Fixed cells were dropped onto slides, dried at
50C for 20 min and then incubated for 20 min in 10 mg/ml Hoescht-33258
(Sigma), diluted in 0.05 M sodium phosphate buffer, pH 6.8 at room temper-
ature. Slides were irradiated with UV-A (365 nm) for 90 min and then incu-
bated in prewarmed 2X SSC for 1 hr at 62C. Slides were stainedwith freshly
prepared Leishman’s stain (Sigma) (diluted 1:3 in 0.05 M sodium phosphate
buffer, pH 6.8) for 2 min. Slides were dried and mounted with Eukitt
Mounting Media (Electron Microscopy Sciences) under a coverslip. Cells
in metaphase were visualized with a 100X objective on a Zeiss Axioskop 2
microscope and 50 spreads scored blind to the observer.
Protein Purification
GST-FLAG-GgBRCA1 (1–300, WT, and V26A) and GST-FLAG-claspin 1–331
were purified from BL21/DE3 bacterial cells following isopropyl-L-thio-B-D-
galactopyranoside (IPTG) induction as previously described [32]. Purifica-
tion of His-UbcH5c and His- BARD1was previously described [32]. Purifica-
tion of His-BRCA11-304 and His-BARD11-320 as a RING heterodimer was
performed as previously described [32]. Rabbit E1 (Affiniti) and mammalian
ubiquitin (Affiniti) were purchased commercially.
Ubiquitin Ligation Assay In Vitro
The procedure used for the in vitro ubiquitin ligation assay was performed
as previously described [32] with a reaction mixture (30 AL) that contained
50 mmol/L Tris-HCl (pH 7.5), 5 mmol/L MgCl2, 2 mmol/L ATP, 0.6 mmol/L
DTT, 1 mg mammalian ubiquitin, 40 ng E1, 0.3 mg UbcH5c, 1 mg His-
BRCA11-304/His-BARD11-320, and 1 mg of GST-FLAG-claspin 1–331. The
ubiquitylation productswere detected by immunoblottingwith the indicated
antibodies.
Preparation of Samples for Liquid Chromatography-Tandem Mass
Spectrometry
After in vitro ubiquitin ligation, samples were resolved by SDS-PAGE. Gels
were silver stained and excised spots were enzymatically cleaved in gel
as previously described [34]. Each spot was reduced with 10 mM DTT at
56C for 30 min and alkylated with 50 mM iodoacetamide (Sigma, Buchs,
Switzerland) in the dark for 30 min followed by enzymatic cleavage with
2 mg Trypsin (Promega).
LC-MS/MS Analysis
The samples were analyzed on a LTQ Orbitrap XL mass spectrometer (MS;
Thermo-Fisher Scientific, Bremen, Germany), which was connected online
to a nanoelectrospray ion source (Thermo-Fisher Scientific, Bremen,
Germany). Peptide separation was carried out using an Eksigent Tempo
nano LC 1D+ System (Eksigent Technologies, Dublin, CA, USA) equipped
with a RP-HPLC column (75 mm 3 15 cm) packed in-house with C18 resin
(Magic C18 AQ 3 mm; Michrom BioResources, Auburn, CA, USA) using
a linear gradient from 96% solvent A (0.15% formic acid, 2% acetonitrile)
and 4% solvent B (0.15% formic acid, 98% acetonitrile) to 25% solvent B
over 40 min at a flow rate of 0.3 ml/min. We injected 4 ml of each sample
per liquid chromatography-tandem mass spectrometry (LC-MS/MS) run
for analysis. After every two samples, a peptide mixture containing 200
fmol of [Glu1]-Fibrinopeptide B human (Sigma, Buchs, Switzerland) was
analyzed by LC-MS/MS to constantly monitor the performance of the LC-
MS/MS system.
Acquired MS2 scans were searched against the UniProtKB/Swiss-Prot
protein database (release v56.9) using the Sorcerer-SEQUEST v4.0.4
search algorithm, which was run on the SageN Sorcerer (Thermo Electron).
In silico trypsin, digestion was performed after lysine and arginine (unless
followed by proline) tolerating two missed cleavages in fully tryptic
peptides. Allowed monoisotopic mass error for the precursor ions was 50
ppm. A fixed residue modification parameter was set for carboxyamidome-
thylation (+57.021464 Da) of cysteine residues. Oxidation of methionine
(+15.99492 Da) and ubiquitylation (+114.042923 Da) of lysine residues
were set as variable residue modification parameter. For scoring,
a maximum of two missed cleavages were considered. Search results
were evaluated on the Trans Proteomic Pipeline (TPP v4.02).
Supplemental Information
Supplemental Information includes four figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article online
at http://dx.doi.org/10.1016/j.cub.2012.07.034.
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